Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer

Shuying Liu, Shunqiang Li, Bailiang Wang, Wenbin Liu, Mihai Gagea, Huiqin Chen, Joohyuk Sohn, Napa Parinyanitikul, Tina Primeau, Kim Anh Do, George F. Vande Woude, John Mendelsohn, Naoto T. Ueno, Gordon Mills, Debu Tripathy, Ana M. Gonzalez-Angulo

Research output: Contribution to journalArticle

Abstract

There is compelling evidence that oncogenic MET and PIK3CA signaling pathways contribute to breast cancer. However, the activity of pharmacologic targeting of either pathway is modest. Mechanisms of resistance to these monotherapies have not been clarified. Currently, commonly used mouse models are inadequate for studying the HGF-MET axis because mouse HGF does not bind human MET. We established human HGF-MET paired mouse models. In this study, we evaluated the cooperative effects of MET and PIK3CA in an environment with involvement of human HGF in vivo Oncogenic MET/PIK3CA synergistically induced aggressive behavior and resistance to each targeted therapy in an HGF-paracrine environment. Combined targeting of MET and PI3K abrogates resistance. Associated cell signaling changes were explored by functional proteomics. Consistently, combined targeting of MET and PI3K inhibited activation of associated oncogenic pathways. We also evaluated the response of tumor cells to HGF stimulation using breast cancer patient-derived xenografts (PDX). HGF stimulation induced significant phosphorylation of MET for all PDX lines detected to varying degrees. However, the levels of phosphorylated MET are not correlated with its expression, suggesting that MET expression level cannot be used as a sole criterion to recruit patients to clinical trials for MET-targeted therapy. Altogether, our data suggest that combined targeting of MET and PI3K could be a potential clinical strategy for breast cancer patients, where phosphorylated MET and PIK3CA mutation status would be biomarkers for selecting patients who are most likely to derive benefit from these cotargeted therapy.

Original languageEnglish (US)
Pages (from-to)399-412
Number of pages14
JournalMolecular cancer therapeutics
Volume18
Issue number2
DOIs
StatePublished - Feb 1 2019
Externally publishedYes

Fingerprint

Breast Neoplasms
Phosphatidylinositol 3-Kinases
Heterografts
Proteomics
Therapeutics
Biomarkers
Phosphorylation
Clinical Trials
Mutation
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Liu, S., Li, S., Wang, B., Liu, W., Gagea, M., Chen, H., ... Gonzalez-Angulo, A. M. (2019). Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer. Molecular cancer therapeutics, 18(2), 399-412. https://doi.org/10.1158/1535-7163.MCT-18-0710

Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer. / Liu, Shuying; Li, Shunqiang; Wang, Bailiang; Liu, Wenbin; Gagea, Mihai; Chen, Huiqin; Sohn, Joohyuk; Parinyanitikul, Napa; Primeau, Tina; Do, Kim Anh; Vande Woude, George F.; Mendelsohn, John; Ueno, Naoto T.; Mills, Gordon; Tripathy, Debu; Gonzalez-Angulo, Ana M.

In: Molecular cancer therapeutics, Vol. 18, No. 2, 01.02.2019, p. 399-412.

Research output: Contribution to journalArticle

Liu, S, Li, S, Wang, B, Liu, W, Gagea, M, Chen, H, Sohn, J, Parinyanitikul, N, Primeau, T, Do, KA, Vande Woude, GF, Mendelsohn, J, Ueno, NT, Mills, G, Tripathy, D & Gonzalez-Angulo, AM 2019, 'Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer', Molecular cancer therapeutics, vol. 18, no. 2, pp. 399-412. https://doi.org/10.1158/1535-7163.MCT-18-0710
Liu, Shuying ; Li, Shunqiang ; Wang, Bailiang ; Liu, Wenbin ; Gagea, Mihai ; Chen, Huiqin ; Sohn, Joohyuk ; Parinyanitikul, Napa ; Primeau, Tina ; Do, Kim Anh ; Vande Woude, George F. ; Mendelsohn, John ; Ueno, Naoto T. ; Mills, Gordon ; Tripathy, Debu ; Gonzalez-Angulo, Ana M. / Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer. In: Molecular cancer therapeutics. 2019 ; Vol. 18, No. 2. pp. 399-412.
@article{b54ca194d54e44af9a552e3767a40bf4,
title = "Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer",
abstract = "There is compelling evidence that oncogenic MET and PIK3CA signaling pathways contribute to breast cancer. However, the activity of pharmacologic targeting of either pathway is modest. Mechanisms of resistance to these monotherapies have not been clarified. Currently, commonly used mouse models are inadequate for studying the HGF-MET axis because mouse HGF does not bind human MET. We established human HGF-MET paired mouse models. In this study, we evaluated the cooperative effects of MET and PIK3CA in an environment with involvement of human HGF in vivo Oncogenic MET/PIK3CA synergistically induced aggressive behavior and resistance to each targeted therapy in an HGF-paracrine environment. Combined targeting of MET and PI3K abrogates resistance. Associated cell signaling changes were explored by functional proteomics. Consistently, combined targeting of MET and PI3K inhibited activation of associated oncogenic pathways. We also evaluated the response of tumor cells to HGF stimulation using breast cancer patient-derived xenografts (PDX). HGF stimulation induced significant phosphorylation of MET for all PDX lines detected to varying degrees. However, the levels of phosphorylated MET are not correlated with its expression, suggesting that MET expression level cannot be used as a sole criterion to recruit patients to clinical trials for MET-targeted therapy. Altogether, our data suggest that combined targeting of MET and PI3K could be a potential clinical strategy for breast cancer patients, where phosphorylated MET and PIK3CA mutation status would be biomarkers for selecting patients who are most likely to derive benefit from these cotargeted therapy.",
author = "Shuying Liu and Shunqiang Li and Bailiang Wang and Wenbin Liu and Mihai Gagea and Huiqin Chen and Joohyuk Sohn and Napa Parinyanitikul and Tina Primeau and Do, {Kim Anh} and {Vande Woude}, {George F.} and John Mendelsohn and Ueno, {Naoto T.} and Gordon Mills and Debu Tripathy and Gonzalez-Angulo, {Ana M.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1158/1535-7163.MCT-18-0710",
language = "English (US)",
volume = "18",
pages = "399--412",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer

AU - Liu, Shuying

AU - Li, Shunqiang

AU - Wang, Bailiang

AU - Liu, Wenbin

AU - Gagea, Mihai

AU - Chen, Huiqin

AU - Sohn, Joohyuk

AU - Parinyanitikul, Napa

AU - Primeau, Tina

AU - Do, Kim Anh

AU - Vande Woude, George F.

AU - Mendelsohn, John

AU - Ueno, Naoto T.

AU - Mills, Gordon

AU - Tripathy, Debu

AU - Gonzalez-Angulo, Ana M.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - There is compelling evidence that oncogenic MET and PIK3CA signaling pathways contribute to breast cancer. However, the activity of pharmacologic targeting of either pathway is modest. Mechanisms of resistance to these monotherapies have not been clarified. Currently, commonly used mouse models are inadequate for studying the HGF-MET axis because mouse HGF does not bind human MET. We established human HGF-MET paired mouse models. In this study, we evaluated the cooperative effects of MET and PIK3CA in an environment with involvement of human HGF in vivo Oncogenic MET/PIK3CA synergistically induced aggressive behavior and resistance to each targeted therapy in an HGF-paracrine environment. Combined targeting of MET and PI3K abrogates resistance. Associated cell signaling changes were explored by functional proteomics. Consistently, combined targeting of MET and PI3K inhibited activation of associated oncogenic pathways. We also evaluated the response of tumor cells to HGF stimulation using breast cancer patient-derived xenografts (PDX). HGF stimulation induced significant phosphorylation of MET for all PDX lines detected to varying degrees. However, the levels of phosphorylated MET are not correlated with its expression, suggesting that MET expression level cannot be used as a sole criterion to recruit patients to clinical trials for MET-targeted therapy. Altogether, our data suggest that combined targeting of MET and PI3K could be a potential clinical strategy for breast cancer patients, where phosphorylated MET and PIK3CA mutation status would be biomarkers for selecting patients who are most likely to derive benefit from these cotargeted therapy.

AB - There is compelling evidence that oncogenic MET and PIK3CA signaling pathways contribute to breast cancer. However, the activity of pharmacologic targeting of either pathway is modest. Mechanisms of resistance to these monotherapies have not been clarified. Currently, commonly used mouse models are inadequate for studying the HGF-MET axis because mouse HGF does not bind human MET. We established human HGF-MET paired mouse models. In this study, we evaluated the cooperative effects of MET and PIK3CA in an environment with involvement of human HGF in vivo Oncogenic MET/PIK3CA synergistically induced aggressive behavior and resistance to each targeted therapy in an HGF-paracrine environment. Combined targeting of MET and PI3K abrogates resistance. Associated cell signaling changes were explored by functional proteomics. Consistently, combined targeting of MET and PI3K inhibited activation of associated oncogenic pathways. We also evaluated the response of tumor cells to HGF stimulation using breast cancer patient-derived xenografts (PDX). HGF stimulation induced significant phosphorylation of MET for all PDX lines detected to varying degrees. However, the levels of phosphorylated MET are not correlated with its expression, suggesting that MET expression level cannot be used as a sole criterion to recruit patients to clinical trials for MET-targeted therapy. Altogether, our data suggest that combined targeting of MET and PI3K could be a potential clinical strategy for breast cancer patients, where phosphorylated MET and PIK3CA mutation status would be biomarkers for selecting patients who are most likely to derive benefit from these cotargeted therapy.

UR - http://www.scopus.com/inward/record.url?scp=85061023665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061023665&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-18-0710

DO - 10.1158/1535-7163.MCT-18-0710

M3 - Article

VL - 18

SP - 399

EP - 412

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 2

ER -